Novo Nordisk appoints Maziar Mike Doustdar as CEO

Novo Nordisk (NVO) announced that Maziar Mike Doustdar has been appointed as president and Chief Executive Officer, effective August 7. Doustdar succeeds Lars Fruergaard Jorgensen, who will step down as president and CEO on the same date. The company also announced other executive-level changes, effective August 7. “Mike Doustdar, currently Novo Nordisk’s executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk’s International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk’s affiliates outside of the US and employs nearly 20,000 people… Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board’s decision to appoint Maziar Mike Doustdar as president and chief executive officer,” the company added.